To add to the insightful guest post above (
)
I'd add that one thing that I suspect is that the patent renewal which occurred after the "redesign" was probably rubber-stamped-- and not examined too carefully to see whether it OUGHT to retain that patent protection.... much less
new protections on that basis.
I don't know-- haven't looked. But it definitely occurred to me and my DH. That might have been no accident, that 'redesign' that did bugger all to help people actually carry or use the device. Basically making it 'anti-roll' was about the ONLY improvement at all, there were several 'features' that actually make it worse--and the mechanism is utterly unchanged.
What I don't know is when the original patent protection was set to expire (before then). My hypothesis is that it was sometime between 2010 and 2015.
Thanks, also to Eragon and other other non-US members who have pointed out just HOW awful this is compared with other countries. Morally bankrupt is about the only way that I can think about this industry and what it does to the US population that pays so much for it's R&D budgets to begin with. It's outrageous. To a point that leaves me frankly speechless.
This technology cost the pharmaceutical companies that have held the patent
almost nothing to develop. To MONETIZE, sure-- they had to go through the FDA for that, so yeah, lawyer-fun-times. That cost, those applications.
But the device itself was already paid for and WELL-developed for use with atropine. By the military-- er, or the research that supports innovations in the military, that is. The armed forces and space program both work this way-- when technology is not considered tactically advantageous to keep classified, then it becomes fair game for intellectual property transfer... and so it was with pre-determined dosing, autoinjection devices.
Narcan and Epinephrine were pretty obvious candidates, since dosing is reasonably standard "per person" in emergent situations.
All of that adds up to what SHOULD have been a robust market all along, with respect to generic devices. Blame our patent protections for pharmaceuticals.